The Union Ministry of Health and Family Welfare has issued a detailed advisory directing States and Union Territories to enforce existing regulations on stem cell therapy with greater strictness. Dated September 16, 2026, the advisory makes clear that stem cell treatments may be offered as standard care in routine clinical practice only for specific disease conditions approved by the Ministry. It explicitly bars unapproved routine or commercial use, with particular emphasis on Autism Spectrum Disorder, and highlights the legal consequences of violations.
Context Behind the Advisory
The directive follows a Supreme Court judgment delivered on January 30, 2026, in the matter of Yash Charitable Trust and Others versus Union of India and Others. In that ruling, the Court held that stem cell therapies for Autism Spectrum Disorder cannot be offered as a regular clinical service outside approved and monitored research or clinical trial settings. The Court noted the lack of established scientific evidence on the safety and efficacy of such treatments for autism and observed that offering them as routine care fails the reasonable standard of care expected of medical practitioners.
The Health Ministry’s advisory reiterates the existing regulatory framework governing stem cell research and therapy. It has been sent to all States and Union Territories that have adopted the Clinical Establishments (Registration and Regulation) Act, 2010, with a request that state and district regulatory authorities, along with clinical establishments, ensure full compliance.
Strict Limits on Routine Clinical Use
According to the advisory, stem cell therapy is permitted as standard care only for disease conditions and indications included in the official list approved by the Ministry of Health and Family Welfare. Beyond this approved list, stem cell interventions are restricted to the research context. Research involving stem cells that have undergone more than minimal manipulation falls under the regulation of the Central Drugs Standard Control Organisation, while other research requires appropriate approvals under the relevant guidelines.
Only safe and appropriately performed hematopoietic stem cell transplantation is recognised as standard of care for a defined set of indications, primarily certain blood disorders, leukemias, lymphomas, and related conditions. Mesenchymal stem cell transplantation is not recommended for any disease condition as standard care.
Specific Restrictions on Autism Spectrum Disorder
The advisory pays particular attention to Autism Spectrum Disorder. It states that the therapeutic use of any type of stem cell for autism must remain restricted to duly approved clinical trials. These trials are required to follow the National Guidelines for Stem Cell Research, 2017, jointly issued by the Indian Council of Medical Research and the Department of Biotechnology, along with other applicable government instructions.
Unproven stem cell interventions, including those promoted for autism, must not be offered as routine, standard, or commercial clinical services. The Ministry has underscored that such treatments lack the scientific backing required for routine clinical use and should not be marketed or administered outside properly regulated research settings.
Role of the National Medical Commission
Reinforcing the Health Ministry’s position, the National Medical Commission issued its own advisory in early September 2026. The Commission reiterated that stem cell therapy may be offered as standard clinical care only for the approved indications listed by the Ministry. It advised registered medical practitioners, medical institutions, and State Medical Councils that any unauthorised administration, prescription, promotion, or advertisement of stem cell therapy beyond the approved indications constitutes professional misconduct.
State Medical Councils have been asked to examine alleged violations actively and, where professional misconduct is established after due process, to take appropriate disciplinary action.
Penalties and Consequences of Non-Compliance
The advisory draws attention to the consequences of ignoring these directions. The Supreme Court made clear that non-compliance must attract consequences. These include findings of professional misconduct under Regulation 7.22 of the Indian Medical Council Regulations, 2002. Additionally, action can be taken under Sections 32 and 40 of the Clinical Establishments (Registration and Regulation) Act, 2010, which provide for cancellation of registration of the clinical establishment and the imposition of financial penalties.
The Ministry has requested concerned authorities to ensure that these provisions are applied where violations occur, thereby protecting patients from unproven and potentially harmful interventions.
Why the Emphasis on Evidence-Based Practice Matters
Stem cell therapy has been aggressively marketed in India for a range of conditions, including autism, cerebral palsy, spinal cord injuries, and certain neurological disorders. Families seeking solutions for complex and often lifelong conditions have sometimes paid substantial amounts for treatments that lack established clinical evidence. The regulatory framework aims to prevent exploitation while still allowing legitimate research to proceed under controlled conditions.
By limiting routine clinical use to approved indications and confining experimental applications to properly authorised trials, the authorities seek to balance scientific progress with patient safety. Clinical trials conducted under the National Guidelines for Stem Cell Research include requirements for ethical oversight, informed consent, and, where applicable, provision for compensation in case of injury.
Implications for Patients, Doctors, and Clinics
For patients and families, the advisory serves as a clear warning against seeking or accepting stem cell treatments outside the approved list or authorised research settings. Legitimate options remain available for the listed conditions, primarily through established hematopoietic stem cell transplantation protocols. For other conditions, participation in approved clinical trials may be possible where such trials are ongoing and appropriately regulated.
Medical practitioners and clinical establishments are expected to review their practices immediately. Offering or advertising stem cell therapy for unapproved indications as a commercial service exposes them to professional and legal risks. Clinics that have been promoting such treatments for autism or other non-approved conditions are now under greater scrutiny.
State and district authorities responsible for regulating clinical establishments have been tasked with monitoring compliance. This includes ensuring that only approved indications are treated as standard care and that any research activity follows the prescribed pathways.
Broader Regulatory Landscape
The advisory forms part of a wider effort to strengthen oversight of regenerative medicine and advanced therapies in India. Earlier guidelines and evidence-based reviews have already restricted the routine use of stem cell approaches for certain other conditions where the quality of evidence was found to be insufficient. The consistent message across these documents is that therapies must demonstrate adequate safety and efficacy before they enter routine clinical practice.
Research continues to be encouraged within the proper regulatory framework. The distinction between approved standard care and experimental research is intended to protect the public while enabling the generation of high-quality evidence that may, in the future, expand the list of approved indications.
The Health Ministry’s September 2026 advisory, together with the National Medical Commission’s parallel guidance and the Supreme Court’s earlier directions, establishes a clear national position. Stem cell therapy has a recognised role in specific, evidence-supported applications. Outside those boundaries, it must remain confined to regulated research. Strict enforcement by States and Union Territories is expected to reduce the availability of unproven treatments and safeguard patients from interventions that have not yet met the required standards of scientific validation.
Read more – sevendollarmiracle.com
